Non-Hodgkin Lymphoma
Oncology 1 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q2 2029
Purinostat Mesylate for Injection
Chengdu Zenitar Biomedical Technology Co., Ltd
Estimated · aging NCT07011056
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 48 industry trials with a known mechanism of action.
Kinase Inhibitor
20 trials 5 active 7 sponsors
DNA
5 trials 3 active 3 sponsors
CD20-directed Cytolytic Antibody
4 trials 1 active 2 sponsors
Thalidomide Analog
4 trials 2 sponsors
Programmed Death Receptor-1 Blocking Antibody
4 trials 2 sponsors
PI3K-delta/PI3K-gamma
3 trials 2 sponsors
CD30-directed Immunoconjugate
2 trials 1 sponsor
CD19/CD3
2 trials 1 sponsor
AKT1/AKT2/AKT3
1 trials 1 sponsor
Proteasome Inhibitor
1 trials 1 sponsor
BCL-2 Inhibitor
1 trials 1 sponsor
Nuclear Export Inhibitor
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
397 industry-sponsored trials across 203 sponsors
Showing 2 of 2 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Eli Lilly | Pirtobrutinib | Kinase Inhibitor [EPC] | RECRUITING | 2030-05 | NCT06876662 |
| Eli Lilly | Pirtobrutinib | Kinase Inhibitor [EPC] | RECRUITING | 2030-05 | NCT06876649 |
Showing 39 of 39 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Johnson & Johnson | Ibrutinib | Kinase Inhibitor [EPC] | RECRUITING | 2026-12-31 | NCT01804686 |
| Regeneron | Odronextamab | — | RECRUITING | 2028-03-30 | NCT06091865 |
| Hutchmed | HMPL-760 | — | RECRUITING | 2028-04-30 | NCT07409428 |
| BeOne Medicines | Sonrotoclax | — | RECRUITING | 2028-08-31 | NCT06742996 |
| BeBetter Med Inc | Ifupinostat Hydrochloride for Injection | — | RECRUITING | 2028-12-31 | NCT06792253 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | Purinostat Mesylate for Injection | — | RECRUITING | 2029-06-30 | NCT07011056 |
| Lyell Immunopharma, Inc. | rondecabtagene autoleucel | — | RECRUITING | 2029-12 | NCT07188558 |
| AstraZeneca | AZD0486 | — | RECRUITING | 2030-06-10 | NCT07215585 |
| Kite, A Gilead Company | KITE-753 | — | RECRUITING | 2031-05 | NCT07479797 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | Rocbrutinib | — | RECRUITING | 2031-05-30 | NCT07377578 |
| InnoCare Pharma Inc. | Orelabrutinib | — | RECRUITING | 2031-06-25 | NCT06363994 |
| Grifols Therapeutics LLC | Xembify | — | RECRUITING | 2026-05 | NCT05645107 |
| Karyopharm Therapeutics Inc | Selinexor (combination therapy) | — | ACTIVE NOT RECRUITING | 2026-12 | NCT04442022 |
| BeOne Medicines | zanubrutinib | Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-03 | NCT04002297 |
| Roche | Glofitamab | — | ACTIVE NOT RECRUITING | 2027-10-01 | NCT06047080 |
| Regeneron | Odronextamab | — | ACTIVE NOT RECRUITING | 2028-05-29 | NCT06230224 |
| Bristol-Myers Squibb | Golcadomide | — | ACTIVE NOT RECRUITING | 2028-08-14 | NCT06356129 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | ACTIVE NOT RECRUITING | 2031-03 | NCT05605899 |
| ADC Therapeutics S.A. | Loncastuximab Tesirine | — | ACTIVE NOT RECRUITING | 2026-03-31 | NCT04384484 |
| Incyte Corporation | Tafasitamab | — | ACTIVE NOT RECRUITING | 2026-03-30 | NCT05429268 |
| Roche | Mosunetuzumab | — | ACTIVE NOT RECRUITING | 2025-02-17 | NCT05171647 |
| Nurix Therapeutics, Inc. | NX-5948 | — | NOT YET RECRUITING | 2029-10 | NCT07516093 |
| Johnson & Johnson | Bendamustine | — | COMPLETED | 2021-06-30 | NCT01776840 |
| Roche | Rituximab | CD20-directed Cytolytic Antibody [EPC] | COMPLETED | 2021-06-30 | NCT02406092 |
| Novartis | Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy | — | COMPLETED | 2021-05-06 | NCT03570892 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | COMPLETED | 2021-03-18 | NCT03391466 |
| Seagen Inc. | brentuximab vedotin | CD30-directed Immunoconjugate [EPC] | COMPLETED | 2018-08-15 | NCT01777152 |
| Teva Branded Pharmaceutical Products R&D, Inc. | lipegfilgrastim | — | COMPLETED | 2017-08-29 | NCT02044276 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Bendamustine hydrochloride | — | COMPLETED | 2015-06-18 | NCT01596621 |
| Johnson & Johnson | Ibrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2015-06-05 | NCT01646021 |
| Roche | Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) | — | COMPLETED | 2015-01 | NCT01724021 |
| Millennium Pharmaceuticals, Inc. | Rituximab 375 mg/m^2 | — | COMPLETED | 2014-01-01 | NCT00722137 |
| Cephalon | Bendamustine | — | COMPLETED | 2012-06 | NCT01073163 |
| Teva Branded Pharmaceutical Products R&D, Inc. | bendamustine | — | COMPLETED | 2012-03-31 | NCT00877006 |
| Nektar Therapeutics | NKTR-255 at 1.5 µg/kg | — | TERMINATED | 2024-05-22 | NCT05664217 |
| TG Therapeutics, Inc. | Ublituximab | — | TERMINATED | 2022-05-31 | NCT02793583 |
| Bristol-Myers Squibb | Lenalidomide | Thalidomide Analog [EPC] | TERMINATED | 2011-03-01 | NCT01021423 |
| Incyte Corporation | parsaclisib | — | WITHDRAWN | 2030-08-15 | NCT04849715 |
| Acerta Pharma BV | acalabrutinib | — | WITHDRAWN | 2020-06 | NCT02735876 |
Showing 100 of 173 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Ossium Health, Inc. | — | — | RECRUITING | 2026-05-31 | NCT05589896 |
| Xynomic Pharmaceuticals, Inc. | abexinostat | — | RECRUITING | 2026-07-31 | NCT03936153 |
| BioInvent International AB | BI-1206 | — | RECRUITING | 2026-09-30 | NCT03571568 |
| BeOne Medicines | BGB-16673 | — | RECRUITING | 2026-11 | NCT05006716 |
| Ryvu Therapeutics SA | MEN1703 | — | RECRUITING | 2026-12 | NCT06534437 |
| Cho Pharma Inc. | CHO-H01 | — | RECRUITING | 2026-12-23 | NCT05950165 |
| Genfleet Therapeutics (Shanghai) Inc. | GFH009 | — | RECRUITING | 2026-12-31 | NCT06375733 |
| Estrella Biopharma, Inc. | EB103 | — | RECRUITING | 2026-12-31 | NCT06343311 |
| Pell Bio-Med Technology Co., Ltd. | CD19-targeted chimeric antigen receptor T-cell | — | RECRUITING | 2026-12-31 | NCT05326243 |
| Miltenyi Biomedicine GmbH | zamtocabtagene autoleucel (MB-CART2019.1) | — | RECRUITING | 2026-12-31 | NCT04792489 |
| AstraZeneca | Surovatamig | — | RECRUITING | 2027-03-10 | NCT06526793 |
| Beijing Biotech | Autologous CD19/CD22 dual-target CAR-T module | — | RECRUITING | 2027-03-14 | NCT07523555 |
| VIVUS LLC | VI-0609 | — | RECRUITING | 2027-03-31 | NCT06915246 |
| Shanghai AbelZeta Ltd. | Prizloncabtagene autoleucel | — | RECRUITING | 2027-03-31 | NCT05800977 |
| Vironexis Biotherapeutics Inc. | — | — | RECRUITING | 2027-06 | NCT06533579 |
| Cellectis S.A. | UCART20x22 | — | RECRUITING | 2027-08 | NCT05607420 |
| Bristol-Myers Squibb | BMS-986458 | — | RECRUITING | 2027-10-28 | NCT06090539 |
| Allogene Therapeutics | Fludarabine | — | RECRUITING | 2027-12 | NCT06500273 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | Rocbrutinib | — | RECRUITING | 2027-12-31 | NCT07189065 |
| TICAROS Co., Ltd. | TC011 | — | RECRUITING | 2028-02-11 | NCT07473167 |
| AstraZeneca | Surovatamig | — | RECRUITING | 2028-02-28 | NCT06564038 |
| AstraZeneca | AZD4512 | — | RECRUITING | 2028-03-01 | NCT07123454 |
| BeOne Medicines | BGB-16673 | — | RECRUITING | 2028-12-02 | NCT06634589 |
| Lyell Immunopharma, Inc. | Rondecabtagene autoleucel (ronde-cel) | — | RECRUITING | 2028-12-31 | NCT05826535 |
| BeiGene | BGB-16673 | — | RECRUITING | 2029-01-31 | NCT05294731 |
| AstraZeneca | AZD3470 | — | RECRUITING | 2029-04-30 | NCT06137144 |
| Roche | Obinutuzumab | CD20-directed Cytolytic Antibody [EPC] | RECRUITING | 2029-11-30 | NCT05533775 |
| CRISPR Therapeutics AG | CTX112 | — | RECRUITING | 2030-01 | NCT05643742 |
| Kite, A Gilead Company | Cyclophosphamide | DNA | RECRUITING | 2030-02 | NCT04989803 |
| Genmab | Epcoritamab | — | RECRUITING | 2032-11 | NCT05283720 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQB3702 tablets+Chemotherapy regimen | — | RECRUITING | 2026-03 | NCT06566586 |
| Indapta Therapeutics, INC. | IDP-023 | — | RECRUITING | 2025-12-30 | NCT06119685 |
| GI Cell, Inc. | GIC-102 | — | RECRUITING | 2025-12-30 | NCT05880043 |
| IDP Discovery Pharma S.L. | IDP-121 | — | RECRUITING | 2025-12-22 | NCT05908409 |
| Guangzhou Excelmab Inc. | EX103 injection | — | RECRUITING | 2025-10 | NCT06021678 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | Relma-cel | — | RECRUITING | 2025-04-30 | NCT06479356 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | DPX-Survivac | — | RECRUITING | 2024-10 | NCT04920617 |
| Curocell Inc. | CRC01 | — | RECRUITING | 2023-05 | NCT04836507 |
| Actuate Therapeutics Inc. | 9-ING-41 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT03678883 |
| Cellectar Biosciences, Inc. | Iopofosine I 131 single dose | — | ACTIVE NOT RECRUITING | 2026-06-22 | NCT02952508 |
| Regeneron | Odronextamab | — | ACTIVE NOT RECRUITING | 2026-07-06 | NCT03888105 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Nemtabrutinib | — | ACTIVE NOT RECRUITING | 2026-09-18 | NCT03162536 |
| Novartis | Rapcabtagene autoleucel single agent | — | ACTIVE NOT RECRUITING | 2027-06-30 | NCT03960840 |
| Genmab | Epcoritamab (monotherapy) | — | ACTIVE NOT RECRUITING | 2027-09 | NCT04542824 |
| Roche | Mosunetuzumab (Cohorts A-C) | — | ACTIVE NOT RECRUITING | 2028-07-31 | NCT05207670 |
| Werewolf Therapeutics, Inc. | WTX-330 | — | ACTIVE NOT RECRUITING | 2028-08 | NCT06939283 |
| Merck | Pembrolizumab (+) Berahyaluronidase alfa | — | ACTIVE NOT RECRUITING | 2028-11-08 | NCT06504394 |
| Genmab | Epcoritamab | — | ACTIVE NOT RECRUITING | 2029-01 | NCT03625037 |
| Merck | Zilovertamab vedotin | — | ACTIVE NOT RECRUITING | 2029-05-17 | NCT05458297 |
| Galapagos NV | — | — | ACTIVE NOT RECRUITING | 2029-07-01 | NCT06561425 |
| Eli Lilly | Pirtobrutinib | Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2030-05 | NCT07162181 |
| Hutchmed | HMPL-760 planned dose 1 | — | ACTIVE NOT RECRUITING | 2026-05-12 | NCT06601504 |
| Merck | Zilovertamab vedotin | — | ACTIVE NOT RECRUITING | 2026-04-22 | NCT05144841 |
| Sichuan Baili Pharmaceutical Co., Ltd. | GNC-038 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT05627856 |
| BeiGene | BGB-11417 | — | ACTIVE NOT RECRUITING | 2025-07-18 | NCT05471843 |
| Genmab | Epcoritamab | — | ACTIVE NOT RECRUITING | 2025-04 | NCT05201248 |
| Cothera Bioscience, Inc | Sepantronium Bromide | — | ACTIVE NOT RECRUITING | 2025-03-01 | NCT05263583 |
| Takeda | TAK-007 | — | ACTIVE NOT RECRUITING | 2024-06-16 | NCT05020015 |
| Roche | Mosunetuzumab (IV) | — | ACTIVE NOT RECRUITING | 2024-01-30 | NCT03671018 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | Relmacabtagene Autoleucel | — | ACTIVE NOT RECRUITING | 2024-01-21 | NCT06093841 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | — | ACTIVE NOT RECRUITING | 2023-10-25 | NCT04718883 |
| Zhejiang Teruisi Pharmaceutical Inc. | TRS005 | — | NOT YET RECRUITING | 2026-09-01 | NCT07035379 |
| Zhejiang Teruisi Pharmaceutical Inc. | TRS005 | — | NOT YET RECRUITING | 2027-01 | NCT06886139 |
| ImmunityBio, Inc. | CD19 t-haNK- IV Administration | — | NOT YET RECRUITING | 2027-12 | NCT07477366 |
| Shanghai EpimAb Biotherapeutics Co., Ltd. | EMB07 | — | NOT YET RECRUITING | 2028-06-30 | NCT07432022 |
| Beijing InnoCare Pharma Tech Co., Ltd. | ICP-490 | — | NOT YET RECRUITING | 2028-07 | NCT06845241 |
| TORL Biotherapeutics, LLC | TORL-5-700 | — | NOT YET RECRUITING | 2029-03-31 | NCT07439653 |
| Nurix Therapeutics, Inc. | NX-5948 | — | NOT YET RECRUITING | 2033-05 | NCT07520006 |
| Kite, A Gilead Company | Brexucabtagene Autoleucel (KTE-X19) | — | COMPLETED | 2026-03-25 | NCT02625480 |
| BeiGene | Zanubrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2026-01-09 | NCT04116437 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | COMPLETED | 2025-11-24 | NCT05459571 |
| Epizyme, Inc. | Tazemetostat | — | COMPLETED | 2025-09-26 | NCT02875548 |
| BeiGene | Zanubrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2025-03-31 | NCT05068440 |
| Loxo Oncology, Inc. | Pirtobrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2025-01-27 | NCT03740529 |
| Kite, A Gilead Company | Axicabtagene ciloleucel | — | COMPLETED | 2024-12-20 | NCT03105336 |
| Cyteir Therapeutics, Inc. | CYT-0851 | — | COMPLETED | 2024-11-30 | NCT03997968 |
| Oncternal Therapeutics, Inc | Cirmtuzumab (2-16 kg/mg) plus Ibrutinib | — | COMPLETED | 2024-09-25 | NCT03088878 |
| Miltenyi Biomedicine GmbH | MB-CART20.1 | — | COMPLETED | 2024-09-17 | NCT03664635 |
| BeiGene | Ociperlimab | — | COMPLETED | 2024-08-30 | NCT05267054 |
| BeiGene | BGB-10188 | — | COMPLETED | 2024-08-28 | NCT04282018 |
| Merck | Pembrolizumab | Programmed Death Receptor-1 Blocking Antibody [EPC] | COMPLETED | 2023-12-14 | NCT04875195 |
| Roche | Mosunetuzumab | — | COMPLETED | 2023-10-12 | NCT03677141 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | COMPLETED | 2023-10-12 | NCT03761056 |
| AstraZeneca | Capivasertib | AKT1/AKT2/AKT3 | COMPLETED | 2023-08-22 | NCT05008055 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | COMPLETED | 2023-07-27 | NCT02348216 |
| SecuraBio | Duvelisib | PI3K-delta/PI3K-gamma | COMPLETED | 2023-07-24 | NCT04038359 |
| Antengene Corporation | ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle | — | COMPLETED | 2023-05-31 | NCT03992339 |
| TCR2 Therapeutics | TC-110 T Cells | — | COMPLETED | 2023-02-24 | NCT04323657 |
| Kite, A Gilead Company | Axicabtagene Ciloleucel | — | COMPLETED | 2023-01-30 | NCT04002401 |
| Novartis | Tisagenlecleucel | — | COMPLETED | 2022-12-22 | NCT02445248 |
| Nordic Nanovector | 10 MBq/kg Betalutin | — | COMPLETED | 2022-10-25 | NCT01796171 |
| MorphoSys AG | MOR00208 (formerly Xmab 5574) | — | COMPLETED | 2022-04-06 | NCT01685008 |
| TG Therapeutics, Inc. | Umbralisib | — | COMPLETED | 2022-02-15 | NCT03364231 |
| Roche | Lenalidomide | Thalidomide Analog [EPC] | COMPLETED | 2021-12-15 | NCT02600897 |
| BeiGene | Zanubrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2021-10-08 | NCT03332017 |
| Epizyme, Inc. | Tazemetostat | — | COMPLETED | 2021-08-24 | NCT01897571 |
| Novartis | Tisagenlecleucel | — | COMPLETED | 2021-07-27 | NCT03610724 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI376 | — | COMPLETED | 2021-07-27 | NCT04298879 |
| AbbVie | azacitadine | — | COMPLETED | 2021-03-12 | NCT02265731 |
| CARsgen Therapeutics Co., Ltd. | CAR-CD19 T Cells | — | COMPLETED | 2021-01-20 | NCT03994913 |
Showing 100 of 183 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Excyte Biopharma Ltd | YK012 | — | RECRUITING | 2026-06-30 | NCT06565689 |
| Iksuda Therapeutics Ltd. | IKS03 | — | RECRUITING | 2026-09 | NCT05365659 |
| Beijing Yongtai Ruike Biotechnology Company Ltd | RC19D2 cell injection | — | RECRUITING | 2026-09-05 | NCT06047197 |
| Emercell SAS | allogenic natural killer cells | — | RECRUITING | 2026-09-30 | NCT07044050 |
| ADC Therapeutics S.A. | Loncastuximab Tesirine | — | RECRUITING | 2026-10-30 | NCT04970901 |
| Bioray Laboratories | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection | — | RECRUITING | 2026-11-20 | NCT05741359 |
| InSilico Medicine Hong Kong Limited | ISM8207 | — | RECRUITING | 2026-11-30 | NCT06445517 |
| Chongqing Precision Biotech Co., Ltd | PIC1 Injection | — | RECRUITING | 2026-12 | NCT07456371 |
| ADC Therapeutics S.A. | Loncastuximab Tesirine | — | RECRUITING | 2026-12 | NCT05660395 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | LV009 Injection | — | RECRUITING | 2026-12-03 | NCT07284927 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | LP-168 tablet | — | RECRUITING | 2026-12-31 | NCT04993690 |
| Antengene Biologics Limited | ATG-031 | — | RECRUITING | 2026-12-31 | NCT06028373 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | BAFF-R CAR-T cells | — | RECRUITING | 2027-01 | NCT07369492 |
| Axter Therapeutics (Beijing) Co., Ltd | AXT-1003 | — | RECRUITING | 2027-03 | NCT06484985 |
| GenomeFrontier Therapeutics TW Co., Ltd. | GF-CART01 | — | RECRUITING | 2027-03 | NCT06703892 |
| FBD Biologics Limited | HCB101 | — | RECRUITING | 2027-05-30 | NCT05892718 |
| Imugene Limited | Azer-cel | — | RECRUITING | 2027-06 | NCT03666000 |
| Imbioray (Hangzhou) Biomedicine Co., Ltd. | IBR900 cell injection | — | RECRUITING | 2027-07-30 | NCT07073833 |
| Carna Biosciences, Inc. | Docirbrutinib | — | RECRUITING | 2027-09 | NCT05602363 |
| Autolus Limited | AUTO1 | — | RECRUITING | 2027-11 | NCT06173518 |
| Schrödinger, Inc. | SGR-1505 | — | RECRUITING | 2027-11 | NCT05544019 |
| NovaOnco Therapeutics Co., Ltd. | XS-04 tablet | — | RECRUITING | 2027-11-01 | NCT06820268 |
| Newave Pharmaceutical Inc | LP-168 | — | RECRUITING | 2027-12-31 | NCT04775745 |
| LTZ Therapeutics, Inc. | LTZ-301 | — | RECRUITING | 2028-02 | NCT07121946 |
| Marker Therapeutics, Inc. | MT-601 | — | RECRUITING | 2028-02-28 | NCT05798897 |
| ImmunityBio, Inc. | CD19 t-haNK | — | RECRUITING | 2028-03 | NCT06334991 |
| AstraZeneca | AZD0486 IV | — | RECRUITING | 2028-04-19 | NCT04594642 |
| Nanjing IASO Biotechnology Co., Ltd. | Rapamycin | — | RECRUITING | 2028-05-21 | NCT06743503 |
| Vittoria Biotherapeutics | Senza5 CART5 | — | RECRUITING | 2028-08-30 | NCT06420089 |
| Verismo Therapeutics | SynKIR-310 | — | RECRUITING | 2028-09 | NCT06544265 |
| MSD R&D (China) Co., Ltd. | MK-1045 | — | RECRUITING | 2028-09-30 | NCT06189391 |
| TCRx Therapeutics Co.Ltd | KSV01 Injection | — | RECRUITING | 2028-12-31 | NCT07260812 |
| Roche | SC Mosunetuzumab | — | RECRUITING | 2029-09-15 | NCT05169515 |
| Nurix Therapeutics, Inc. | NX-2127 | — | RECRUITING | 2026-05 | NCT04830137 |
| OncoNano Medicine, Inc. | ONM-501 | — | RECRUITING | 2026-04-30 | NCT06022029 |
| CytoCares Inc | CC312 | — | RECRUITING | 2026-03 | NCT06037018 |
| Hangzhou GluBio Pharmaceutical Co., Ltd. | GLB-002 | — | RECRUITING | 2026-01-31 | NCT06219356 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | Rocbrutinib | — | RECRUITING | 2025-12-31 | NCT06251180 |
| Acepodia Biotech, Inc. | Cyclophosphamide | DNA | RECRUITING | 2025-09 | NCT05653271 |
| Caribou Biosciences, Inc. | Cyclophosphamide | DNA | RECRUITING | 2025-08 | NCT04637763 |
| SIRPant Immunotherapeutics, Inc. | SIRPant-M | — | RECRUITING | 2025-06 | NCT05967416 |
| FamiCordTx | FCTX-CL19-1 (Tarcidomgen Kimleucel) | — | RECRUITING | 2025-06 | NCT06593145 |
| Luminary Therapeutics | BAFF CAR-T | — | RECRUITING | 2025-05-01 | NCT05312801 |
| Regeneron | cemiplimab | — | ACTIVE NOT RECRUITING | 2026-05-31 | NCT02651662 |
| Miltenyi Biomedicine GmbH | MB-CART19.1 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT03853616 |
| 3D Medicines | 3D189 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT05320809 |
| Synthekine | SYNCAR-001 | — | ACTIVE NOT RECRUITING | 2026-06-24 | NCT05665062 |
| Kite, A Gilead Company | KITE-197 | — | ACTIVE NOT RECRUITING | 2026-07 | NCT06079164 |
| Novartis | PIT565 | — | ACTIVE NOT RECRUITING | 2026-08-20 | NCT05397496 |
| Bristol-Myers Squibb | CC-122 | — | ACTIVE NOT RECRUITING | 2026-10-31 | NCT05688475 |
| Johnson & Johnson | JNJ-90009530 | — | ACTIVE NOT RECRUITING | 2027-01-06 | NCT05784441 |
| Genmab | Epcoritamab | — | ACTIVE NOT RECRUITING | 2028-11 | NCT05206357 |
| Poseida Therapeutics, Inc. | P-CD19CD20-ALLO1 | — | ACTIVE NOT RECRUITING | 2029-03 | NCT06014762 |
| BeOne Medicines | BGB-21447 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT05828589 |
| Sana Biotechnology | SC262 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06285422 |
| Zhejiang Teruisi Pharmaceutical Inc. | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection | — | ACTIVE NOT RECRUITING | 2025-07-31 | NCT05395533 |
| Bio-Path Holdings, Inc. | L-Bcl-2 antisense oligonucleotide | — | ACTIVE NOT RECRUITING | 2025-04 | NCT04072458 |
| Nkarta, Inc. | NKX019 | — | ACTIVE NOT RECRUITING | 2025-03-31 | NCT05020678 |
| iOnctura | IOA-244 | — | ACTIVE NOT RECRUITING | 2023-12-13 | NCT04328844 |
| Eli Lilly | LOXO-338 | — | ACTIVE NOT RECRUITING | 2023-06-14 | NCT05024045 |
| Daiichi Sankyo Co., Ltd. | DS-3201b | — | ACTIVE NOT RECRUITING | 2022-12-31 | NCT02732275 |
| Tessa Therapeutics | CD30.CAR-T | — | ACTIVE NOT RECRUITING | 2022-11-22 | NCT04526834 |
| Sinocelltech Ltd. | SCTB35 injection | — | NOT YET RECRUITING | 2026-10 | NCT06318884 |
| Eli Lilly | LY4152199 - IV | — | NOT YET RECRUITING | 2027-04 | NCT07101328 |
| Chipscreen Biosciences, Ltd. | CS08399 | — | NOT YET RECRUITING | 2029-08 | NCT07583771 |
| Ascentage Pharma Group Inc. | APG-3288 | — | NOT YET RECRUITING | 2029-12 | NCT07424833 |
| Roche | Glofitamab | — | COMPLETED | 2025-10-15 | NCT05364424 |
| Johnson & Johnson | JNJ-64619178 | — | COMPLETED | 2025-09-25 | NCT03573310 |
| Regeneron | Odronextamab multiple dose levels | — | COMPLETED | 2025-08-21 | NCT02290951 |
| Prelude Therapeutics | PRT2527 | — | COMPLETED | 2025-06-12 | NCT05665530 |
| Fate Therapeutics | FT522 | — | COMPLETED | 2025-06-06 | NCT05950334 |
| Otsuka Pharmaceutical Co., Ltd. | OPB-111077 | — | COMPLETED | 2025-03-25 | NCT04049825 |
| Werewolf Therapeutics, Inc. | WTX-330 | — | COMPLETED | 2024-12-23 | NCT05678998 |
| NeoImmuneTech | Efineptakin alfa | — | COMPLETED | 2024-12-18 | NCT05075603 |
| Roche | Glofitamab | — | COMPLETED | 2024-12-02 | NCT03467373 |
| Merus B.V. | MCLA-145 | — | COMPLETED | 2024-11-07 | NCT03922204 |
| Pfizer | Maplirpacept | — | COMPLETED | 2024-11-06 | NCT05896774 |
| Juno Therapeutics, a Subsidiary of Celgene | JCAR017 (lisocabtagene maraleucel) single-dose schedule | — | COMPLETED | 2024-05-16 | NCT02631044 |
| BeiGene | Zanubrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2024-03-28 | NCT04436107 |
| TG Therapeutics, Inc. | TG-1801 | — | COMPLETED | 2024-02-21 | NCT03804996 |
| Sutro Biopharma, Inc. | STRO-001 | — | COMPLETED | 2024-02-15 | NCT03424603 |
| Juno Therapeutics, a Subsidiary of Celgene | CC-97540 | — | COMPLETED | 2024-02-01 | NCT04231747 |
| VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Zilovertamab vedotin | — | COMPLETED | 2023-12-18 | NCT03833180 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | LP-168 tablet | — | COMPLETED | 2023-08-21 | NCT05917964 |
| Nektar Therapeutics | NKTR-255 | — | COMPLETED | 2023-04-24 | NCT04136756 |
| Epizyme, Inc. | Tazemetostat | — | COMPLETED | 2023-04-03 | NCT04537715 |
| Corvus Pharmaceuticals, Inc. | CPI-006 | — | COMPLETED | 2022-12-28 | NCT03454451 |
| Bayer | Elimusertib (BAY1895344) | — | COMPLETED | 2022-12-02 | NCT03188965 |
| Prelude Therapeutics | PRT543 | — | COMPLETED | 2022-11-16 | NCT03886831 |
| Celldex Therapeutics | CDX-1140 | — | COMPLETED | 2022-09-13 | NCT03329950 |
| Incyte Corporation | Parsaclisib | — | COMPLETED | 2022-06-27 | NCT03424122 |
| Roche | GDC-0853 | — | COMPLETED | 2022-03-08 | NCT01991184 |
| Adagene Inc | ADG106 | — | COMPLETED | 2022-01-24 | NCT03707093 |
| Zhejiang DTRM Biopharma | DTRMWXHS-12 | — | COMPLETED | 2021-11-17 | NCT03836768 |
| Adagene (Suzhou) Limited | ADG106 | — | COMPLETED | 2021-11-01 | NCT03802955 |
| Roche | Glofitamab | — | COMPLETED | 2021-10-26 | NCT04313608 |
| Shanghai YingLi Pharmaceutical Co. Ltd. | YY-20394 | — | COMPLETED | 2021-09-30 | NCT04279405 |
| AstraZeneca | AZD4573 | — | COMPLETED | 2021-09-30 | NCT03263637 |
| Opna Bio LLC | PLX2853 | — | COMPLETED | 2021-06-07 | NCT03297424 |
| Nordic Nanovector | Betalutin | — | COMPLETED | 2021-06-04 | NCT02658968 |
Novel Drugs by Company (New molecular entities)
Reformulations (6 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Generic Drugs (4 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs